FN2 Earnings Intelligence
Boston Scientific Corporation earnings overview
Latest Boston Scientific Corporation (BSX) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
Boston Scientific Corporation
Boston Scientific delivered solid Q2 operating results, but the investment case now depends on whether strength in Interventional Cardiology, Neuromodulation, and Endoscopy can offset WATCHMAN and EP weakness. The restructuring plan, product pipeline, and strategic transactions provide possible longer-term support, while the repeated guidance reduction makes execution the central issue.
Boston Scientific Corporation
Boston Scientific delivered Q1 FY2026 results that beat on both lines: 9.4% organic revenue growth and adjusted EPS of $0.80 versus $0.79 consensus. However, the stock's trajectory has been defined by the guidance reduction that accompanied those results. Management lowered full-year organic growth to 6.5%-8% and adjusted EPS to $3.34-$3.41, citing unexpected headwinds in electrophysiology, WATCHMAN, and urology. Shares initially rose approximately 9% on the earnings day but subsequently drifted about 13% lower, trading at $45.38 as of July 29, 2026, a 40% discount to the $75.45 analyst consensus target. The dislocation reflects unresolved concerns about the sustainability of EP growth amid intensifying PFA competition from Medtronic, J&J, and Abbott, WATCHMAN volume softness, urology underperformance, and integration risk from the pending Penumbra acquisition. Core growth drivers…
Boston Scientific Corporation
The current analysis supports a constructive but conditional view: strong demand in electrophysiology and WATCHMAN, product expansion, and higher guidance support continued growth, while margin, execution, competitive, and integration risks must be monitored.
Boston Scientific Corporation
The supplied analysis supports a constructive growth case: strong Q2 operating growth, raised guidance, and continued adoption of FARAPULSE and WATCHMAN provide evidence of resilient demand. The case still depends on offsetting tariff and ACURATE-related pressure, executing acquisitions, and achieving regulatory and reimbursement milestones.
Boston Scientific Corporation
The supplied analysis supports a constructive operating thesis: resilient demand in electrophysiology and a broader product and acquisition pipeline can sustain growth, while tariff offsets, China pricing, regulatory timing, and integration execution are the key tests.
Boston Scientific Corporation
The supplied analysis supports a constructive but qualified view: strong demand for pulsed-field ablation and Watchman, new product launches, international expansion, and acquisitions can support growth, but the outlook depends on execution amid competition, pricing pressure, regulatory timing, and integration demands.
Boston Scientific Corporation
Boston Scientific's Q3 results support a constructive growth thesis: strong FARAPULSE adoption, Watchman momentum, and portfolio expansion drove an outlook raise. The thesis remains sensitive to clinical-trial uncertainty, competition, pricing, and foreign exchange.
Get the BSX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.